Innovent Biologics, Inc. Overview
Pro stress-test →Innovent Biologics is a biopharmaceutical company principally engaged in research, development, production and sales of innovative medicines for cancer, cardiovascular and metabolic, autoimmune and eye diseases. As one of the leading biotechnology companies in China listed on the Hong Kong Exchange in 2018, Innovent has 12 commercialized oncology products and three commercialized nononcology products as of March 2025.
Strategic Profile
Pro stress-test →Its core asset is Tyvyt, a PD-1 inhibitor included in the National Reimbursement Drug Lists for first-line treatment of five major cancers. Innovent has over 30 strategic collaborations with global pharmaceutical or biotech companies, such as Eli Lilly, Roche Group, Incyte, and others. Among its upcoming pipelines, the potential blockbuster is Mazdutide, a therapy for obesity and type 2 diabetes.
Competitive Landscape
Pro stress-test →Innovent Biologics is one of the leading biotechnology companies in China. The company competes with both domestic Chinese biotech firms and global pharmaceutical companies in oncology, immunology, and metabolic disease spaces. Key differentiators include its established commercial portfolio, regulatory approvals on reimbursement lists, and major global partnerships.
Industry Context
Innovent Biologics, Inc. operates in Biopharmaceuticals / Oncology and Immunology.
Key facts
Founded: 2011 · Headquarters: Suzhou, China · Employees: 6,190 · Revenue: RMB 10B+ · Market cap: $146.1B HKD